Takeda Pharmaceutical (TAK) Common Equity: 2018-2025

  • Takeda Pharmaceutical's Common Equity fell 7.38% to $45.5 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $45.5 billion, marking a year-over-year decrease of 7.38%. This contributed to the annual value of $45.5 billion for FY2025, which is 9.73% down from last year.
  • According to the latest figures from Q1 2025, Takeda Pharmaceutical's Common Equity is $45.5 billion, which was down 7.38% from $49.1 billion recorded in Q1 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Common Equity peaked at $49.1 billion during Q1 2024, and registered a low of $45.5 billion during Q1 2025.
  • Moreover, its 3-year median value for Common Equity was $48.0 billion (2023), whereas its average is $47.5 billion.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Common Equity grew by 12.65% in 2021, and later fell by 7.38% in 2025.
  • Takeda Pharmaceutical's Common Equity (Quarterly) stood at $48.9 billion in 2021, then climbed by 0.03% to $48.9 billion in 2022, then decreased by 1.81% to $48.0 billion in 2023, then increased by 2.17% to $49.1 billion in 2024, then declined by 7.38% to $45.5 billion in 2025.
  • Its Common Equity stands at $45.5 billion for Q1 2025, versus $49.1 billion for Q1 2024 and $48.0 billion for Q1 2023.